INTRODUCTION
============

Rapid response teams (RRTs) are implemented in hospitals to prevent serious adverse events such as cardiac arrest, unexpected admission to the intensive care unit (ICU), and death \[[@b1-acc-2019-00675]\]. Numerous single-center studies have reported associations of RRTs with reductions in inhospital mortality and cardiopulmonary arrest \[[@b2-acc-2019-00675]-[@b5-acc-2019-00675]\]. However, the potential impacts of RRT activation on in-hospital mortality and cardiopulmonary arrest remain controversial. Although a recent systematic review suggested associations of RRTs with reductions in in-hospital mortality and cardiopulmonary arrest \[[@b6-acc-2019-00675]\], other meta-analyses of RRT studies reported only weak evidence to support an overall reduction in in-hospital mortality \[[@b7-acc-2019-00675],[@b8-acc-2019-00675]\]. This discrepancy may be attributable to factors such as heterogeneity in study populations and differences in activation criteria, composition, and activation quality of RRTs.

Recent developments in early diagnosis and management of cancer have led to improvements in long-term prognosis of cancer patients \[[@b9-acc-2019-00675]\]. Despite declining cancer death rates, however, malignancy-related complications or treatment-associated side effects remain clinically challenging and worsen patient prognoses. Previous studies reported an association between early intervention (i.e., before development of severe organ failure) and better outcomes despite the inherently high acuity level in this population \[[@b10-acc-2019-00675],[@b11-acc-2019-00675]\]. Compared with non-cancer patients, cancer patients experienced higher rates of in-hospital mortality after RRT activation \[[@b12-acc-2019-00675]\]. Moreover, as RRTs are often activated during the end-of-life stage, RRT activation might play an important role in discussions regarding goals of care or initiation of palliative care for a cancer patient \[[@b12-acc-2019-00675]-[@b14-acc-2019-00675]\]. To date, few studies have investigated the utilization and outcomes of RRTs in cancer patients. Therefore, the current study aimed to analyze utilization of an RRT and the associations of related factors with mortality in a population of cancer patients.

MATERIALS AND METHODS
=====================

Design
------

We retrospectively reviewed the RRT activation records at Seoul St. Mary's Hospital from January 2014 to December 2018. Seoul St. Mary's Hospital is a tertiary teaching hospital in Korea that admits approximately 85,000 adults per year. Approval for this study was obtained from the Institutional Review Board of Seoul St. Mary's Hospital. The requirement for informed consent was waived by the ethical review board.

Patients and Setting
--------------------

The study objective was to determine the utilization and outcomes of oncology patients who required RRT activation. The hospital RRT, which is called the St. Mary's Advanced Life Support Team, was implemented in June 2013 with the aims of reducing in-hospital mortality and improving the quality of hospital care. Since 2016, medical staff affiliated with the RRT have provided 24 hour/day coverage of all departments except pediatrics.

RRT Activation and Screening
----------------------------

The criteria for RRT activation are shown in [Table 1](#t1-acc-2019-00675){ref-type="table"}. In this study, we summarized and re-classified these criteria into seven categories: heart rate change, blood pressure change, respiratory rate change, SaO~2~ change, altered mental status, staff concern, and other reason. RRT nurses performed primary screening and checks and then called an RRT physician. RRT activation was defined as the process wherein intensivists or residents arrive at the patient's bedside and provide medical treatment, consultation, or decisions about transfer to the ICU. At each activation, the RRT transported a portable multi-monitor and the point-of-care blood analysis system (Epoc; Alere, Waltham, MA, USA). Patients were also protected by an electronic medical record (EMR)-based screening system and were automatically screened if a clinical value determined by the EMR satisfied RRT activation criteria. The RRT charge nurse assessed the condition of each patient and recommended RRT activation to the ward staff or nurses as needed.

Data Collection
---------------

We collected data on baseline demographics, including age and sex, from the EMR database. Comorbidity data were collected for the studied patients and used to calculate the Charlson comorbidity score index \[[@b15-acc-2019-00675]\]. For each patient, we also recorded hospital length of stay, number of days between admission and RRT activation, nature of the event leading to RRT activation, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and Modified Early Warning Score (MEWS). The APACHE II scores were collected for all patients with RRT activation, regardless of ICU transfer. The study outcomes were survival and ICU transfer status within 24 hours after RRT activation.

Statistical Analysis
--------------------

Statistically significant differences between groups were analyzed using the chi-square, Wilcoxon rank-sum, Student t-test, or Welch's test as appropriate. Factors associated with in-hospital mortality were assessed by logistic regression. Data are expressed as mean±standard deviation for normally distributed continuous variables and median and interquartile range for non-normally distributed continuous data. Categorical data are reported as number (%). A two-tailed P-value \<0.05 was considered statistically significant. All statistical analyses were performed using R 3.4.1 version (R Foundation, Vienna, Austria).

RESULTS
=======

A total of 457 patients required RRT activation during the indicated study period, including 164 patients with cancer. Notably, utilization of RRT resources during the study period was higher for cancer patients than non-cancer patients, with 2.80 vs. 1.38 per 1,000 patient discharges. [Table 2](#t2-acc-2019-00675){ref-type="table"} presents the baseline characteristics of the included patients. Non-cancer patients were younger and less likely to have diabetes, renal failure, congestive heart failure, history of myocardial infarction, cerebrovascular disease, and dementia compared to cancer patients. Cancer patients had a significantly higher Charlson comorbidity score (P\<0.001 vs. non-cancer patients) and higher severity scores of APACHE II and MEWS (P=0.007 and P\<0.001, respectively).

[Figure 1](#f1-acc-2019-00675){ref-type="fig"} depicts the reasons for RRT activation. A change in blood pressure was the most common reason for RRT activation among cancer patients, whereas a change in SaO~2~ was the most common reason among non-cancer patients. Changes in heart rate and blood pressure were significantly more commonly recorded for cancer patients vs. non-cancer patients (23.8% vs. 15.4%, P=0.037 and 37.2% vs. 21.2%, P\<0.001, respectively).

[Table 3](#t3-acc-2019-00675){ref-type="table"} lists the patient outcomes after RRT activation. In this study, cancer patients had a significantly higher rate of inhospital mortality compared with non-cancer patients (39.6% vs. 10.9%, P\<0.001). Moreover, a significantly larger proportion of cancer patients required ICU transfer (51.8% vs. 41.0%, P=0.032). Only two cancer patients (1.2%) had a preexisting do-not-resuscitate (DNR) order. Within 24 hours after RRT activation, 24 patients (14.6%) experienced a change in code status, and palliative care involvement after RRT activation was reported for only 11 patients (10.6%).

The presence of cancer was independently associated with in-hospital mortality on multivariate analysis (adjusted odds ratio \[OR\], 2.09; 95% confidence interval \[CI\], 1.11 to 3.93; P=0.023). Patients with a preexisting DNR order or who experienced a change in code status within 24 hours after RRT activation were excluded from the analysis. Other independent risk factors for hospital mortality were ICU transfer (adjusted OR, 3.13; 95% CI, 1.63 to 5.99; P\<0.001), Charlson comorbidity score (adjusted OR, 1.24; 95% CI, 1.08 to 1.42; P\<0.001), APACHE- II score (adjusted OR, 1.05; 95% CI, 1.00 to 1.11; P=0.0437), and number of days between admission and RRT activation (adjusted OR, 1.02; 95% CI, 1.01 to 1.03; P=0.005) ([Figure 2](#f2-acc-2019-00675){ref-type="fig"}).

[Table 4](#t4-acc-2019-00675){ref-type="table"} lists the demographic differences between survivors and non-survivors among patients with malignancy. Patients with a preexisting DNR order and those who experienced a change in code status within 24 hours after RRT activation were excluded from this analysis. Notably, in cancer patients, non-survivors had significantly higher APACHE-II score and MEWS and a longer interval between admission and RRT activation than survivors. Unsurprisingly, a significantly larger proportion of patients requiring ICU transfer was observed among non-survivors relative to survivors. After adjusting for potential confounding factors, APACHE II score remained significantly associated with in-hospital mortality (adjusted OR, 1.08; 95% CI, 1.01 to 1.15; P=0.027). ICU transfer was also independently associated with in-hospital mortality (adjusted OR, 2.52; 95% CI, 1.04 to 6.11, P=0.040) ([Table 5](#t5-acc-2019-00675){ref-type="table"}).

DISCUSSION
==========

In this study, which aimed to evaluate the utilization and outcomes of RRT and the factors associated with mortality in cancer patients, we found that cancer patients had significantly higher rates of in-hospital mortality and ICU transfer than non-cancer patients. Furthermore, ICU transfer was associated with a higher mortality rate among cancer patients.

Although RRTs have been widely adopted by health systems over the last 20 years \[[@b16-acc-2019-00675]\], previous studies have failed to clarify the effectiveness of these teams for reducing hospital mortality \[[@b6-acc-2019-00675]\], possibly due to discrepancies in study populations, criteria for RRT activation, and quality of RRT activation. Moreover, major cancer centers have implemented RRTs along with advances in chemotherapy and trends in provision of increasingly aggressive treatments \[[@b13-acc-2019-00675],[@b17-acc-2019-00675]\]. However, a previous study reported that adverse outcomes are more common among cancer patients requiring RRT than among non-cancer patients \[[@b17-acc-2019-00675]\].

In this study, cancer patients were more likely to require RRT activation during the study period and ICU transfer after an RRT event compared to their counterparts without cancer. Additionally, cancer patients also had significantly higher disease severity scores (APACHE II score, MEWS) and Charlson comorbidity score. As expected, cancer patients requiring RRT had a significantly higher rate of in-hospital mortality compared to their counterparts without cancer, and this association remained significant after adjusting for confounding factors, including severity scores and Charlson comorbidity score. These findings suggest inherently higher mortality rates among cancer patients, especially those experiencing acute medical deterioration, than among non-cancer patients. These results are consistent with the findings of previous studies in which cancer patients were found to have an inherently high acuity level \[[@b15-acc-2019-00675],[@b18-acc-2019-00675]\].

In this study, the in-hospital mortality rate was significantly higher among cancer patients who required ICU transfer after an RRT event than among non-cancer patients, consistent with previous studies \[[@b12-acc-2019-00675],[@b19-acc-2019-00675],[@b20-acc-2019-00675]\]. Therefore, determination of key prognostic predictors of poor outcome is crucial to identifying patients who may benefit from ICU admission. In the present study, higher severity scores at the time of RRT activation, especially the APACHE II score, were significantly associated with in-hospital mortality after adjusting for potential confounding factors in cancer patients. The APACHE II scoring system is an accurate measurement of clinical severity and correlates strongly with outcome in critically ill patients \[[@b21-acc-2019-00675]\]. Consistent with our results, previous studies demonstrated effectiveness of APACHE II score for predicting in-hospital mortality of critically ill patients with cancer in need of intensive care \[[@b22-acc-2019-00675],[@b23-acc-2019-00675]\]. Our findings emphasize that the prognosis of cancer patients is determined by severity at the time of RRT activation regardless of malignancy status.

Recently, several studies have emphasized the role of RRT in end-of-life care provided to cancer patients. Although the RRT primarily aims to detect reversible deterioration, the death process is a frequent trigger of RRT activation \[[@b13-acc-2019-00675]\]. One previous large, multi-center, randomized controlled trial observed an association of RRTs with increase in DNR orders \[[@b24-acc-2019-00675]\], while Coventry et al. \[[@b25-acc-2019-00675]\] reported that RRT calls for patients with pre-existing DNR orders are not uncommon. In the latter study, 15.7% of patients with a pre-established DNR order required RRT activation. Furthermore, a recent review indicated that up to one-third of RRT calls involved patients receiving endof- life care \[[@b13-acc-2019-00675]\]. Consistent with those previous studies, we found that a fairly large number of RRT events involved patients receiving end-of-life care. Specifically, 14.6% of cancer patients showed a change in code status within 24 hours after RRT, and 10.6% were receiving palliative care. Therefore, a better understanding of the role of the RRT during provision of end-of-life care is needed to ensure that patients receive appropriate palliative and comfort care.

The present study had several limitations. First, this was a retrospective study with a relatively small number of patients. Therefore, selection bias may have affected the significance of our findings. Furthermore, our study was conducted at a single institution, which may have limited the generalizability of our findings. Second, this study did not evaluate the time to intervention, defined as the interval from the earliest time when the screening criteria were met until the time when RRT management was initiated \[[@b11-acc-2019-00675],[@b26-acc-2019-00675]\]. However, previous studies reported that early recognition and timely treatment of patients were important contributors to the success of RRT \[[@b1-acc-2019-00675],[@b11-acc-2019-00675]\]. Further studies are warranted to determine the impact of time to intervention in cancer patients who require RRT.

In conclusion, cancer patients in this study who required RRT had significantly higher rates of mortality and ICU transfer than non-cancer patients. The presence of cancer was independently associated with mortality. In patients with malignancy, higher severity scores were an independent predictor of in-hospital mortality. Considering the increasing utilization and expanding role of RRT in cancer patients, further research should focus on identifying subgroups of patients who would most benefit from ICU admission or palliative care services.

KEY MESSAGES
============

▪ In this study, oncology patients requiring rapid response team activation had significantly higher rates of in-hospital mortality.

▪ Moreover, among oncology patients, higher severity score at the time of rapid response team activation was significantly associated with in-hospital mortality regardless of malignancy.
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![Reasons for rapid response team activation. Changes in heart rate and blood pressure were significantly more common in cancer patients than non-cancer patients. RRT: rapid response team. \*P\<0.05, \*\*P\<0.01.](acc-2019-00675f1){#f1-acc-2019-00675}

![Multivariate analysis for factors independently associated with in-hospital mortality. ICU: intensive care unit; APACHE: Acute Physiology and Chronic Health Evaluation; RRT: rapid response team; OR: odds ratio; CI: confidence interval.](acc-2019-00675f2){#f2-acc-2019-00675}

###### 

Criteria for RRT activation

  Criteria
  ------------------------------------------------------------------------
  Respiratory rate ≤8/min or ≥25/min
  O~2~ Saturation ≤90% for more than 5 minutes with prior oxygen therapy
  pH ≤7.3, PaCO~2~ ≥50 mm Hg, PaO~2~ ≤55 mm Hg, lactic acid ≥2.0 mM/L
  Stridor/accessory muscle use
  Systolic blood pressure ≤85 mm Hg with correlated symptoms or signs
  Heart rate ≤50/min or ≥130/min
  Acute chest pain
  Urine output ≤50/ml in 4 hours
  Sudden alteration of consciousness
  Unexplained agitation or anxiety
  Seizure
  Any serious concerns about overall deterioration

RRT: rapid response team; PaCO~2~: partial pressure of carbon dioxide.

###### 

Baseline patient characteristics

  Variable                           Non-cancer patient (n=293)   Cancer patient (n=164)   P-value
  ---------------------------------- ---------------------------- ------------------------ ---------
  Male sex                           142 (48.5)                   65 (39.6)                0.085
  Age (yr)                           72.0 (59.0--80.0)            63.0 (54.5--72.0)        \<0.001
  Diabetes                           106 (36.2)                   38 (23.2)                0.006
  Renal failure                      61 (20.8)                    7 (4.3)                  \<0.001
  Congestive heart failure           57 (19.5)                    8 (4.9)                  \<0.001
  History of myocardial infarction   60 (20.5)                    10 (6.1)                 \<0.001
  Cerebrovascular disease            51 (17.4)                    14 (8.5)                 0.014
  Peripheral vascular disease        33 (11.3)                    9 (5.5)                  0.060
  Moderate to severe liver disease   10 (3.4)                     11 (6.7)                 0.167
  Dementia                           35 (11.9)                    5 (3.0)                  0.002
  Connective tissue disease          20 (6.8)                     8 (4.9)                  0.529
  Hemiplegia                         13 (4.4)                     2 (1.2)                  0.117
  Charlson comorbidity score         5.0 (3.0--6.0)               7.0 (6.0--9.0)           \<0.001
  APACHE II score                    14.0 (9.0--17.0)             16.0 (10.0--20.0)        0.007
  MEWS                               5.0 (4.0--7.0)               7.0 (5.0--8.0)           \<0.001

Values are presented as number (%) or median (interquartile range).

APACHE: Acute Physiology and Chronic Health Evaluation; MEWS: Modified Early Warning Score.

###### 

Outcome after rapid response team activation

  Variable                                         Non-cancer patient (n=293)   Cancer patient (n=164)   P-value
  ------------------------------------------------ ---------------------------- ------------------------ ---------
  In-hospital mortality                            32 (10.9)                    65 (39.6)                \<0.001
  ICU transfer required                            120 (41.0)                   85 (51.8)                0.032
  In-hospital mortality if ICU transfer required   21 (17.5)                    39 (45.9)                \<0.001
  Pre-existing do-not-resuscitate                  0                            2 (1.2)                  0.248
  Code status change within 24 hours after RRT     4 (1.4)                      24 (14.6)                \<0.001
  Palliative care involvement after RRT            1 (0.6)                      11 (10.6)                \<0.001

Values are presented as number (%).

ICU: intensive care unit; RRT: rapid response team.

###### 

Factors associated with survival in cancer patients

  Variable                                   Survivor (n=97)     Non-survivor^[a](#tfn1-acc-2019-00675){ref-type="table-fn"}^ (n=41)   P-value
  ------------------------------------------ ------------------- --------------------------------------------------------------------- ---------
  Male sex                                   42 (43.3)           14 (34.1)                                                             0.417
  Age (yr)                                   63.0 (55.0--72.0)   62.0 (51.0--72.0)                                                     0.843
  Chemotherapy in last 30 days               35 (36.1)           18 (43.9)                                                             0.502
  Charlson comorbidity score                 7.0 (6.0--8.0)      8.0 (6.0--9.0)                                                        0.067
  APACHE II score                            14.0 (9.0--18.5)    17.0 (13.0--22.0)                                                     0.018
  MEWS                                       6.0 (4.0--8.0)      7.0 (5.5--9.0)                                                        0.004
  Day between admission and RRT activation   4.0 (2.0--13.0)     9.0 (3.0--26.0)                                                       0.032
  ICU transfer                               46 (47.4)           29 (70.7)                                                             0.020
  Status of malignancy                                                                                                                 
   First presentation                        28 (28.9)           10 (24.4)                                                             0.742
   Relapse/refractory                        44 (45.4)           21 (51.2)                                                             0.657
   Extensive disease                         38 (39.2)           21 (51.2)                                                             0.263
   Duration of malignancy                    13.0 (1.0--48.0)    9.0 (2.0--32.0)                                                       0.707

Values are presented as number (%) or median (interquartile range).

APACHE: Acute Physiology and Chronic Health Evaluation; MEWS: Modified Early Warning Score; RRT: rapid response team; ICU: intensive care unit.

Patients who had a preexisting do-not-resuscitate order or change in code status within 24 hours post RRT activation were excluded from analysis.

###### 

Multivariable analyses with logistic regression models for probability of in-hospital mortality

  Variable                                    Adjusted odds ratio (95% CI)   P-value
  ------------------------------------------- ------------------------------ ---------
  Age (yr)                                    0.98 (0.94--1.02)              0.405
  Chemotherapy in last 30 days                0.69 (0.24--1.97)              0.492
  Charlson comorbidity score                  1.20 (0.92--1.55)              0.175
  APACHE II score                             1.08 (1.01--1.15)              0.027
  MEWS                                        1.02 (0.82--1.27)              0.838
  Days between admission and RRT activation   1.01 (1.00--1.03)              0.166
  ICU transfer required                       2.52 (1.04--6.11)              0.040
  Status of malignancy                                                       
   Relapse/refractory                         0.76 (0.24--2.47)              0.653
   Extensive disease                          1.92 (0.79--4.66)              0.151
   Duration of malignancy                     0.99 (0.97--1.00)              0.135

Patients who had a preexisting do-not-resuscitate order or a change in code status within 24 hours post RRT activation were excluded from analysis.

CI: confidence interval; APACHE: Acute Physiology and Chronic Health Evaluation; MEWS: Modified Early Warning Score; RRT: rapid response team; ICU: intensive care unit.
